In a preclinical study [95], a second-generation FLT3-4-1BB-CD3-CAR T cell was engineered by using the anti-human FLT3 antibody-derived ScFv to targeting the FLT3+ tumor cells. This evidence concerns the gene FLT3 and neoplasm.